Brief: Spruce Biosciences' Tildacerfont Fails Cahmelia-203 Study In Adult Classic CAH

Spruce Biosciences

13/03/2024 20:35

March 13 (Reuters) - Spruce Biosciences Inc  SPRB.O :
    * SPRUCE BIOSCIENCES ANNOUNCES TOPLINE RESULTS FROM
CAHMELIA-203
IN ADULT CLASSIC CAH AND CAHPTAIN-205 IN PEDIATRIC CLASSIC CAH
    * SPRUCE BIOSCIENCES : DATA FROM CAHPTAIN-205 STUDY OF
TILDACERFONT IN PEDIATRIC CLASSIC CAH SUPPORTS FURTHER
DOSE-RANGING IN ADDITIONAL DOSING COHORTS
    * SPRUCE BIOSCIENCES INC: CAHMELIA-203 STUDY DID NOT MEET
PRIMARY
EFFICACY ENDPOINT
    * SPRUCE BIOSCIENCES : SEES TOPLINE RESULTS FROM
CAHMELIA-204
STUDY OF TILDACERFONT IN ADULT CLASSIC CAH EVALUATING
GLUCOCORTICOID (GC) REDUCTION IN Q3
    * SPRUCE BIOSCIENCES INC: RESOURCE PRIORITIZATION AND COST
REDUCTIONS EXTEND CASH RUNWAY THROUGH END OF 2025

Source text for Eikon:  ID:nBw5qQXbQa 
Further company coverage:  SPRB.O 

 ((Reuters.Briefs@thomsonreuters.com;))